



IMAGION BIOSYSTEMS LIMITED

(ASX: IBX)

22 July 2020

Results of Annual General Meeting

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), Imagion Biosystems Limited advises the results its 2019 Annual General Meeting held earlier today.

All resolutions were carried on a poll. Details of the resolutions, proxies received, and the votes cast on the poll in respect of each resolution are set out in the attached proxy summary.

-ENDS

About Imagion Biosystems

Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

For further information please visit www.imagionbiosystems.com

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Imagion Biosystems Limited

U.S. Media Contact:

Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630

Australian Media & Investor Relations:

Kyahn Williamson, WE Communications
We-AUImagionBiosystems@we-worldwide.com
+61 (0) 401018828

Imagion Biosystems Limited
Annual General Meeting
Wednesday, 22 July 2020
Voting Results

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth).

| Resolution details | | Instructions given to validly appointed proxies (as at proxy close) | | | | Number of votes cast on the poll (where applicable) | | | Resolution Result | If s250U applies |
|--|-----------------|--|----------------------|--------------------|---------|--|----------------------|----------|-----------------------|------------------|
| Resolution | Resolution Type | For | Against | Proxy's Discretion | Abstain | For | Against | Abstain* | Carried / Not Carried | |
| 1. Adoption of Remuneration Report (non-binding resolution) | Ordinary | 83,113,881 91.34% | 2,089,040 2.30% | 5,787,497 6.36% | 462,733 | 88,951,378 97.71% | 2,089,040 2.29% | 462,733 | Carried | No |
| 2. Re-Election of Director - Ms Dianne Angus | Ordinary | 85,041,042 91.53% | 1,502,773 1.62% | 6,366,336 6.85% | 0 | 92,437,378 98.40% | 1,502,773 1.60% | 0 | Carried | NA |
| 3. Re-Election of Director - Mr Michael Harsh | Ordinary | 85,041,042 91.53% | 1,502,773 1.62% | 6,366,336 6.85% | 0 | 92,437,378 98.40% | 1,502,773 1.60% | 0 | Carried | NA |
| 4. Re-Election of Director - Ms Jovanka Naumoska | Ordinary | 81,648,606 87.88% | 4,895,209 5.27% | 6,366,336 6.85% | 0 | 88,784,942 94.77% | 4,895,209 5.23% | 0 | Carried | NA |
| 5. Ratification of Prior Issue of Shares and New Options April 2020 Follow-on Placement | Ordinary | 76,337,324 89.82% | 2,546,692 3.00% | 6,106,336 7.18% | 210,000 | 83,473,660 97.04% | 2,546,692 2.96% | 210,000 | Carried | NA |
| 6. Approval of future Issue of New Options April 2020 Follow-on Placement | Ordinary | 82,149,856 88.62% | 3,953,959 4.27% | 6,596,336 7.12% | 210,000 | 89,776,192 95.78% | 3,953,959 4.22% | 210,000 | Carried | NA |
| 7. Approval of future Issue of Options to the Lead Manager and Underwriter of the March 2020 Renounceable Rights Offer | Ordinary | 81,319,524 87.72% | 4,784,291 5.16% | 6,596,336 7.12% | 210,000 | 88,945,860 94.90% | 4,784,291 5.10% | 210,000 | Carried | NA |
| 8. Ratification of the Issue of Options to the Lead Manager of the November 2019 Renounceable Rights Issue | Ordinary | 81,483,024 87.90% | 4,620,791 4.98% | 6,596,336 7.12% | 210,000 | 89,109,360 95.07% | 4,620,791 4.93% | 210,000 | Carried | NA |
| 9. Approval of new Equity Incentive Plan | Ordinary | 76,043,486 83.80% | 8,909,435 9.82% | 5,787,497 6.38% | 712,733 | 81,880,983 90.19% | 8,909,435 9.81% | 712,733 | Carried | NA |
| 10. Approval of 10% Placement Facility | Special | 77,220,093 83.34% | 8,369,803 9.03% | 7,070,255 7.63% | 250,000 | 85,320,348 91.07% | 8,369,803 8.93% | 250,000 | Carried | NA |
| 11. Approval of related party benefits under Performance Rights and Options to Mr Robert Proulx | Ordinary | 73,062,945 80.11% | 12,826,628 14.06% | 5,313,578 5.83% | 250,000 | 78,676,523 85.98% | 12,826,628 14.02% | 250,000 | Carried | NA |
| 12. Approval of related party benefits under Options to the Non-Executive Directors | Ordinary | 71,943,687 78.88% | 13,945,886 15.29% | 5,313,578 5.83% | 250,000 | 77,557,265 84.76% | 13,945,886 15.24% | 250,000 | Carried | NA |

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.